EMPULSE
a Phase III trial to evaluate the effect on changes in NT-proBNP, safety and tolerability of once daily oral EMPaglilozin 10 mg compared to placebo, initiated in patients hospitalized for acUte decompensated heart faiLure who have been StabilizEd (EMPULSE)
- Stadium
- klaar
- Middel
- Empagliflozine
- Populatie
- Hartfalen
- Fase
- III
- First Patient In
- 1 juni 2020
- Last Patient In
- 18 februari 2021
- Last Patient Last Visit
- 2 juni 2021
National Lead
